Late on Monday evening Exelixis put out the word that its crucial late-stage study of cabozantinib flunked a comparison study with prednisone for castration-resistant prostate cancer, triggering a restructuring that will eliminate 70% of the jobs at the biotech.
This study was the big one for cabozantinib, but it failed to achieve a statistically significant improvement in overall survival among treatment-resistant patients. The cabo arm averaged an 11.0-month median OS rate compared to 9.8 months for prednisone. The median progression-free survival rate wa...
03:00 Carrier incentives stir debate over 'rewarding' offshoring14
12:06 Republicans have a double standard when it comes to Trump’s threats of ‘retribution’11
14:49 Trump warns of ‘retribution’ for companies that offshore jobs, threatening 35 percent tariff15
23:35 50 Cent $14.5 Mil from Lawyers He Accused Of Sleek Audio Screw Job10